Litcius/Paper detail

Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study

Shiwani Mahajan, Rajesh Srinivasan, Carrie A. Redlich, Sara K. Huston, Kelly Anastasio, Lisa Cashman, Daisy Massey, Andrew Dugan, Dan Witters, Jenny Marlar, Shu‐Xia Li, Zhenqiu Lin, Domonique Hodge, Manas Chattopadhyay, Mark D. Adams, Charles Lee, Lokinendi V. Rao, Chris Stewart, Karthik Kuppusamy, Albert I. Ko, Harlan M. Krumholz

2020The American Journal of Medicine30 citationsDOIOpen Access PDF

Topics & Concepts

SeroprevalenceAntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakImmunologyImmunoglobulin GSerologyOutbreakInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study | Litcius